Azenta Inc

Repligen reported second-quarter revenues of $204.1 million, up 11.9% year over year and exceeding analysts' expectations by 1.1%. The company also beat analysts' EPS and organic revenue estimates, with President and CEO Olivier Loeillot citing 13% organic growth and increased full-year guidance. Among the eight drug development inputs and services stocks tracked, the group's revenues beat consensus estimates by 4.1% on average, while next quarter's revenue guidance came in 0.8% above expectations. Repligen delivered the weakest performance against analyst estimates and the weakest full-year guidance update of the group, yet its stock is up 29.4% since reporting and currently trades at $169.56. Azenta posted the best Q2 with revenues of $161.2 million, up 12% year over year and beating estimates by 8%, while IQVIA reported revenues of $4.37 billion, up 8.7% year over year and exceeding expectations by 1.5%.

Azenta Inc reported total revenue of $161 million for the third quarter of fiscal 2026, up 12% as reported and 9% organically year-over-year, driven by strong performance in biorepositories and its C&I business. Sample Management Solutions revenue reached $88 million, up 14% reported and 9% organically, while Multiomics revenue was $73 million, up 10% reported and 8% organically. Gross margin declined 140 basis points to 46.2%, with Sample Management gross margin down 750 basis points to 45.9% due to lower volumes and quality remediation costs, partially offset by a 550-basis-point improvement in Multiomics gross margin to 46.5%. Adjusted EBITDA margin was approximately 11.4%, down 60 basis points year-over-year but up 610 basis points sequentially, and non-GAAP EPS came in at $0.16. The company repurchased approximately 2.3 million shares for $50 million and ended the quarter with $529 million in cash and marketable securities. For the full year, Azenta expects revenue in the range of $613 million to $618 million, with organic revenue approximately flat to up 1%, and adjusted EBITDA between $59 million and $62 million.

Zacks Investment Research added five stocks to its Zacks Rank Number 1 Strong Buy list on July 16. B2Gold Corp saw its current-year earnings consensus estimate rise 7.7 percent over the last 60 days. Apogee Enterprises and Azenta each recorded a 7.1 percent increase in their current-year earnings consensus estimates over the same period. Afya's current-year earnings consensus estimate climbed 6.5 percent, while Kinross Gold's rose 6.1 percent.

Azenta has completed the sale of its B Medical Systems business to Thelema for a fixed purchase price of $63 million. The deal, which closed on July 1, 2026, was previously announced on December 29, 2025. B Medical Systems, a provider of cold chain medical solutions, was originally acquired by Azenta in 2022. To facilitate the transaction, Azenta Germany GmbH extended a $35 million vendor loan to Thelema, carrying 6% annual interest and maturing in three months. The company stated the divestiture will simplify its portfolio and sharpen focus on core life sciences operations.